Day 2, Main Congress

Time/Room

Grand Ballroom, Level 3

09:00 – 11:00

Symposium 6: Stage 3B Lung Cancer Discussion

From Unresectable to Resectable – The Modern Multidisciplinary Journey

09:00 – 09:12

Staging Stage IIIB NSCLC: EBUS, PET-CT, Molecular Testing and Determining Resectability

09:12 – 09:24

Can Stage IIIB Be Operated On? Current Definitions of Resectability and Surgical Selection

09:24 – 09:36

Neoadjuvant Immunotherapy and Chemo-Immunotherapy: Changing the Treatment Paradigm

09:36 – 09:48

Technical Challenges of Surgery After Induction Therapy: Tips, Pitfalls and Outcomes

09:48 – 10:00

Definitive Chemoradiation or Trimodality Therapy? Where Does Radiation Fit?

10:00 – 10:12

Biomarkers, ctDNA and Response Assessment: Selecting Patients for Conversion Surgery

10:12 – 10:24

Conversion Surgery for Initially Unresectable Stage IIIB Disease: Evidence, Outcomes and Future Directions 

10:24 – 10:36

Adjuvant Therapy After Surgery: Immunotherapy, Targeted Therapy and Long-Term Surveillance

10:36 – 11:00

[Panel Discussion] Which Stage IIIB Patients Should We Aim to Convert to Surgery?

11:00 – 11:30

Opening Ceremony

11:30 – 12:30

Satellite Lunch Symposium by MSD

12:30 – 14:00

Symposium 7: Rare/Uncommon Cancers in the Thoracic Malignancies:

A Multidisciplinary Approach to Challenging Tumours

12:30 – 12:42

Thymic Epithelial Tumours: Contemporary Management from Early to Advanced Disease

12:42 – 12:54

Malignant Pleural Mesothelioma: Surgery, Systemic Therapy and the Future of Multimodality Care

12:54 – 13:06

Mediastinal Germ Cell Tumours: Optimising Outcomes Through Multidisciplinary Management

13:06 – 13:18

Pulmonary Neuroendocrine Tumours: Diagnosis, Classification and Treatment Strategies

13:18 – 13:30

SMARCA4-Deficient and Other Molecularly Defined Rare Thoracic Tumours: New Biology, New Therapeutic Opportunities

13:30 – 13:42

Chest Wall Sarcomas and Rare Pleural Tumours: Surgical Principles and Reconstruction Strategies

13:42 – 14:00

[Panel Discussion] Managing Rare Thoracic Malignancies: When Evidence Is Limited and Multidisciplinary Expertise Matters Most

14:00 – 14:30

Coffee/Tea Break, Exhibition & E-Poster Viewing

Room

Grand Ballroom, Level 3

14:30 – 15:30

Symposium 8: Recap by Pulmonologist, Surgeon & Oncologist (Top 10 papers of the Year)

Room

Residence 5 & 6, Level 3

Residence 2, Level 3

15:30 – 17:00

Symposium 9: SEATS x TSTS x HKTS

Symposium 10: Young Investigation Award Presentations

19:00 – 21:30

SEATS 2026 Gala Dinner (Ticketed)

Day 3, Main Congress

Time/Room

Grand Ballroom, Level 3

09:00 – 10:30

Symposium 11: Stage 4B Resection with Anastomosis

10:30 – 11:00

Coffee/Tea Break, Exhibition & E-Poster Viewing

11:00 – 12:30

Symposium 12: Enhanced Recovery After Surgery (ERAS) in Oncology

12:30 – 13:30

Lunch Break & Exhibition

13:30 – 14:30

Symposium 13: Healthcare Sustainability by SEATS Sustainability Initiative

13:30 – 13:37

What is Healthcare Sustainability?

Amanda Zain, Singapore

13:37 – 13:44

Sustainability in Thoracic Surgery

Ben Dunne, Australia

13:44 – 13:51

Sustainability in Oncology

Roselle de Guzman, Philippines

13:51 – 13:58

Sustainability in Respiratory Medicine

See Kay Choong, Singapore

13:58 – 14:05

Sustainability in Anaesthesia

Poh Pei Kee, Singapore

14:05 – 14:12

Sustainability in Industry

Benish Aslam, Singapore

14:12 – 14:19

SEATS Sustainability Initiative

Lowell Leow, Singapore

14:19– 14:30

Q&A

14:30 – 15:00

Coffee/Tea Break, Exhibition & E-Poster Viewing

15:00 – 16:00

Symposium 14: Quiz Cup

16:00 – 16:30

Closing & Award Ceremony

15 November 2026, Sunday | Multi-Disciplinary Lung Cancer Conference (MLCC)

Time/Room

Grand Ballroom, Level 3

08:00 – 08:30

Morning Registration & Exhibition Viewing

08:30 – 09:00

Networking

09:00 – 09:05

Welcome Address

Amit Jain, Singapore

09:05 – 09:50

Plenary Discussion | Making Incurable Lung Cancers a Chronic Disease – Are We There Yet?

09:50 – 10:05

Networking Coffee Break & Exhibition Viewing

10:05 – 10:50

Session 1 | Beyond Small Molecule Inhibitors in Oncogene Driven Cancers Part 1 – EGFR

Upfront treatments and sequencing for lifetime mutant care

Tackling rare mutations and horizon treatments

Rational cost-effective care for EGFR mutant lung cancer

10:50 – 11:05

Networking Coffee Break & Exhibition Viewing

11:05 – 12:05

Session 2 | Beyond Small Molecule Inhibitors Part 2 – Other Oncogene Driven Lung Cancers

Improving OS in ALK+ lung cancers & early-stage cure rates

MET & BRAF: Upfront vs. delayed TKI, ICI, sequencing, and chemo

KRAS insights: Timing, pairing, and sequencing for ideal outcomes

HER2 driven lung cancers: Current and emerging modalities

12:05 – 13:30

Grand Networking Luncheon

13:30 – 14:15

Session 3 | Functionalising Multi-Omic Interrogation to Guide Rational Individualized Treatments

Next-generation multiplexed AI-powered pathology: Research to translation

Multi-disciplinary molecular tumor boards for n=1 treatments

Practical Case Studies

14:15 – 14:30

Networking Coffee Break & Exhibition Viewing

14:30 – 15:15

Session 4 | Small Cell Lung Cancer – At the Horizon and Beyond

Targeting DLL3 with T cells: How Tarlatamab changed the equation

Beyond DLL3: Novel targets and drug development strategies for SCLC

Combination and sequencing in SCLC: What is on the horizon

15:15 – 15:30

Networking Coffee Break & Exhibition Viewing

15:30 – 16:15

Session 5 | Identifying Immunogenic Lung Cancers and Sustaining Anti-Cancer Immunity

Beyond the singularity of ICIs: Predicting and sustaining responses

Poly-epitope and poly-targeting cancer therapies (TILs, etc.)

B7H3 as a novel target: Pushing boundaries with ADCs, BiTEs, CAR-T, and TILs

16:15 – 16:30

Poster Prize Giving and Closing Remarks